公开(公告)号：US20170152242A1

公开(公告)日：2017-06-01

申请号：US15310337

申请日：2015-05-12

申请人： TEIJIN PHARMA LIMITED

发明人： Akinobu MARUYAMA ,  Susumu TAKEUCHI ,  Yoshimasa TAKAHASHI

IPC分类号： C07D403/04 ,  C07D403/14 ,  C07D401/14 ,  C07D409/14

CPC分类号： C07D403/04 ,  A61K31/497 ,  C07D401/14 ,  C07D403/14 ,  C07D409/14

摘要： Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.

公开(公告)号：US20230167073A1

公开(公告)日：2023-06-01

申请号：US17919186

申请日：2021-04-15

申请人： Teijin Pharma Limited

发明人： Sakae SUGIYAMA ,  Takuya YOKOSAKA ,  Kunio MINAMIZONO ,  Asahi KAWANA ,  Toshiyuki KANEKO ,  Akinobu MARUYAMA ,  Kosuke SASAKI ,  Shinnosuke HOSODA ,  Masaki KOSHIMIZU ,  Susumu TAKEUCHI ,  Kenta KATO ,  Nagasree CHAKKA ,  Brett M. JOHNSON ,  Ryan D. WHITE ,  Wei ZHAO

IPC分类号： C07D239/42 ,  C07D239/48 ,  C07D491/107 ,  C07D487/12 ,  C07D239/47 ,  C07D401/04 ,  C07D239/34 ,  C07D487/04 ,  C07D417/04 ,  C07D413/04 ,  C07D409/04 ,  C07D239/52 ,  C07D237/22 ,  C07D237/14 ,  C07D417/12 ,  C07D409/12 ,  C07D405/12 ,  C07D401/12 ,  C07D403/12 ,  C07D403/04 ,  C07D401/14 ,  C07D231/20 ,  C07D213/30 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D471/04 ,  C07D417/14 ,  C07D413/12 ,  C07D413/14 ,  C07D498/08 ,  C07D491/052

CPC分类号： C07D239/42 ,  C07D239/48 ,  C07D491/107 ,  C07D487/12 ,  C07D239/47 ,  C07D401/04 ,  C07D239/34 ,  C07D487/04 ,  C07D417/04 ,  C07D413/04 ,  C07D409/04 ,  C07D239/52 ,  C07D237/22 ,  C07D237/14 ,  C07D417/12 ,  C07D409/12 ,  C07D405/12 ,  C07D401/12 ,  C07D403/12 ,  C07D403/04 ,  C07D401/14 ,  C07D231/20 ,  C07D213/30 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D471/04 ,  C07D417/14 ,  C07D413/12 ,  C07D413/14 ,  C07D498/08 ,  C07D491/052

摘要： A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar1, Ar2, X1-X3, R1, R3, R7, R8, L1, and L2 are as defined in the specifications.)

公开(公告)号：US20180161329A1

公开(公告)日：2018-06-14

申请号：US15577802

申请日：2016-05-27

申请人： Teijin Pharma Limited

发明人： Tsuyoshi MIZUNO ,  Tomohiro SHIMADA ,  Gen UNOKI ,  Masaru EBISAWA ,  Susumu TAKEUCHI ,  Kunio MINAMIZONO ,  Kosuke SASAKI ,  Takuya YOKOSAKA ,  Junji IGARASHI ,  Akinobu MARUYAMA ,  Hiroshi TAKAHASHI ,  Kyohei HORIE ,  Yuri SAKAI

IPC分类号： A61K31/519 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/551 ,  A61K31/553 ,  C07D471/04 ,  C07D519/00 ,  A61P35/00 ,  A61P19/02 ,  A61P9/10

CPC分类号： A61K31/519 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61P9/10 ,  A61P19/02 ,  A61P35/00 ,  C07D471/04 ,  C07D519/00

摘要： The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20170190694A1

公开(公告)日：2017-07-06

申请号：US15466088

申请日：2017-03-22

申请人： Teijin Pharma Limited

发明人： Akinobu MARUYAMA ,  Hirofumi KAMADA ,  Mika FUJINUMA ,  Susumu TAKEUCHI ,  Hiroshi SAITOH ,  Yoshimasa TAKAHASHI

IPC分类号： C07D409/14 ,  C07D401/14 ,  C07D491/048 ,  C07D401/04 ,  C07D401/12

CPC分类号： C07D409/14 ,  A61K31/4439 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D491/048 ,  A61K2300/00

摘要： Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.